Chang T K, Gonzalez F J, Waxman D J
Department of Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115.
Arch Biochem Biophys. 1994 Jun;311(2):437-42. doi: 10.1006/abbi.1994.1259.
A variety of chemicals, including triacetyloleandomycin (TAO), alpha-naphthoflavone (ANF), and diethyldithiocarbamate (DDC), are widely used as inhibitory probes for select individual human cytochrome P450 (CYP) enzymes, despite the fact that the selectivity of these inhibitors has not been rigorously evaluated. In the present study we take advantage of recent advances in cDNA-directed human P450 expression to evaluate directly the P450 form selectivity of TAO, ANF, and DDC, using a panel of 10 individual cDNA-expressed human P450s. Under experimental conditions known to yield maximal TAO complexation with P450 hemoproteins, TAO (20 microM) inhibited the catalytic activity of expressed CYPs 3A3, 3A4, and 3A5, whereas it did not affect CYPs 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, or 2E1 activity. ANF inhibited not only CYPs 1A1 and 1A2 (IC50 = 0.4-0.5 microM), but it was also similarly effective against CYPs 2C8 and 2C9. Increasing the concentration of ANF to 10 microM led to inhibition of CYP2A6 and CYP2B6. Although a previous study suggested that DDC is a selective inhibitor of CYP2E1, the present investigation shows that at concentrations required to inhibit CYP2E1 (IC50 approximately 125 microM when preincubated with NADPH), DDC also inhibited CYPs 1A1, 1A2, 2A6, 2B6, 2C8, 3A3, and 3A4. Decreasing the concentration of DDC to 10 microM, however, led to inhibition of CYP2A6 (65% inhibition) and CYP2B6 (50% inhibition), but none of the other P450s examined, including CYP2E1. Overall, these results establish that (a) TAO is a selective inhibitor of the human CYP3A subfamily; (b) ANF potently inhibits CYP2C8 and CYP2C9, in addition to CYPs 1A1 and 1A2; and (c) DDC cannot be employed as a diagnostic inhibitory probe for CYP2E1.
包括三乙酰竹桃霉素(TAO)、α-萘黄酮(ANF)和二乙基二硫代氨基甲酸盐(DDC)在内的多种化学物质被广泛用作特定人类细胞色素P450(CYP)酶的抑制性探针,尽管这些抑制剂的选择性尚未得到严格评估。在本研究中,我们利用cDNA指导的人类P450表达的最新进展,使用一组10种个体cDNA表达的人类P450来直接评估TAO、ANF和DDC的P450形式选择性。在已知能使TAO与P450血红蛋白形成最大复合物的实验条件下,TAO(20μM)抑制了表达的CYP 3A3、3A4和3A5的催化活性,而对CYP 1A1、1A2、2A6、2B6、2C8、2C9或2E1的活性没有影响。ANF不仅抑制CYP 1A1和1A2(IC50 = 0.4 - 0.5μM),而且对CYP 2C8和2C9也有类似的抑制效果。将ANF浓度增加到10μM会导致CYP2A6和CYP2B6受到抑制。尽管先前的一项研究表明DDC是CYP2E1的选择性抑制剂,但本研究表明,在抑制CYP2E1所需的浓度下(与NADPH预孵育时IC50约为125μM),DDC也抑制CYP 1A1、1A2、2A6、2B6、2C8、3A3和3A4。然而,将DDC浓度降低到10μM会导致CYP2A6(65%抑制)和CYP2B6(50%抑制)受到抑制,但对其他所检测的P450,包括CYP2E1,均无抑制作用。总体而言,这些结果表明:(a)TAO是人类CYP3A亚家族的选择性抑制剂;(b)ANF除了对CYP 1A1和1A2有强效抑制作用外,还能有效抑制CYP 2C8和CYP 2C9;(c)DDC不能用作CYP2E1的诊断性抑制探针。